Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
AZN
STRONG BUYFLAGAstraZeneca PLC · Healthcare · United Kingdom · $262.5B · Avg Vol: $425M/d
AstraZeneca has strong quality Q72 and momentum M63, but value at V37 is below the calibrated floor, and a positive revision is not accepted corroboration, so stage one fails.
COMPANY DESCRIPTION
AstraZeneca PLC is a global, science-led biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of prescription medicines in oncology, cardiovascular, renal & metabolism, and respiratory & immunology. The company boasts a robust pipeline of innovative therapies, strong R&D capabilities, and global market presence, making it a leader in multiple therapeutic areas. Its commitment to breakthrough science provides a significant competitive moat in the healthcare industry.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 44.4B | 45.8B | 54.1B | 58.7B | 9.8% | 60.4B | 63.2B | 66.8B | 6.6% |
| EPS | 2.12 | 3.84 | 4.54 | 6.60 | 46.0% | 6.47 | 11.00 | — | 66.7% |
| Shares | 1.5B | 1.6B | 1.6B | 1.6B | +0.1% | 1.6B | — | — | — |
| Debt | 29.1B | 28.4B | 30.1B | 29.1B | 0.0% | 34.0B | — | — | — |
| Equity | 37.0B | 39.1B | 40.8B | 48.7B | 9.5% | — | — | — | — |
| Op CF | 9.8B | 10.3B | 11.9B | 14.6B | 14.1% | 14.2B | — | — | — |
| Inv CF | -3.0B | -4.1B | -8.0B | -6.8B | — | — | — | — | — |
| Fin CF | -6.8B | -6.6B | -4.0B | -7.5B | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of AZN are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| AZN | AstraZeneca PLC(you) | $262.5B | 83 | STRONG BUY |
| NOVO-B.CO | Novo Nordisk A/S | $214.5B | 84 | STRONG BUY |
| NOVN.SW | Novartis AG | $297.7B | 87 | STRONG BUY |
| AMGN | Amgen Inc. | $203.0B | 85 | STRONG BUY |
| MRK | Merck & Co., Inc. | $323.7B | 92 | STRONG BUY |
| RO.SW | Roche Holding AG | $336.1B | 92 | STRONG BUY |
| ABBV.MX | AbbVie Inc. | $438.5B | 87 | STRONG BUY |
| GILD | Gilead Sciences, Inc. | $160.5B | 92 | STRONG BUY |
| JNJ | Johnson & Johnson | $634.8B | 84 | STRONG BUY |
| PFE.DE | Pfizer Inc. | $138.0B | 94 | STRONG BUY |
Peer medians: ROE 2.0% · P/E 23.4x · Gross margin 50.0%